DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT
dated as of June 18, 2002
between
WYETH
acting through its Wyeth Consumer Healthcare Division
and
IMPAX LABORATORIES, INC.
for
Loratadine/Pseudoephedrine Combination Tablets
TABLE OF CONTENTS
ARTICLE I DEFINITIONS.......................................................1
ARTICLE II GRANT OF RIGHTS; EXCLUSIVITY.....................................8
ARTICLE III DEVELOPMENT ACTIVITIES AND PATENT LITIGATION....................9
ARTICLE IV SUPPLY..........................................................13
ARTICLE V COMPLIANCE, QUALITY AND ENVIRONMENTAL............................15
ARTICLE VI LICENSE PAYMENTS, ROYALTIES, AND SUPPLY PRICE...................19
ARTICLE VII REPRESENTATIONS AND WARRANTIES.................................23
ARTICLE VIII INDEMNIFICATION AND INSURANCE.................................26
ARTICLE IX TERM AND TERMINATION............................................29
ARTICLE X CONFIDENTIALITY..................................................35
ARTICLE XI TRADEMARKS; INFRINGEMENT OF IMPAX PATENTS.......................37
ARTICLE XII FORCE MAJEURE..................................................38
ARTICLE XIII NOTICES.......................................................39
ARTICLE XIV MISCELLANEOUS..................................................40
-i-
THIS DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT is made and entered into
as of this 1st day of June 2002, between WYETH, a corporation organized and
existing under the laws of Delaware, acting through its Wyeth Consumer
Healthcare Division and having an address at Five Xxxxxxx Xxxxx, Xxxxxxx, Xxx
Xxxxxx 00000 ("WCH") and IMPAX LABORATORIES, INC., a corporation organized and
existing under the laws of Delaware and having an address at 0000 Xxxxxx Xxxxxx,
Xxxxxxxxxxxx, Xxxxxxxxxxxx 00000 ("IMPAX").
RECITALS
WHEREAS, IMPAX has developed two loratadine/pseudoephedrine combination
products and has filed an Abbreviated New Drug Application for each such product
with the United States Food and Drug Administration;
WHEREAS, WCH wishes to license IMPAX's patents and technical
information with respect to such loratadine/pseudoephedrine combination products
and to have IMPAX supply WCH with such products for sale as over-the-counter
drugs; and
WHEREAS, IMPAX is experienced in the manufacture of pharmaceutical
products and is willing to grant such license and supply WCH with such products,
all on the terms and subject to the conditions set forth herein.
NOW, THEREFORE, in consideration of the mutual covenants and agreements
set forth herein, and for good and valuable consideration the receipt and
sufficiency of which are hereby acknowledged, the parties hereto hereby agree as
follows:
ARTICLE I
DEFINITIONS
1.1 Definitions. As used in this Agreement, the following capitalized
terms have the meanings indicated below:
1.1.1 "Affiliate" means, in the case of either Party, any
corporation, joint venture, or other business entity which directly or
indirectly controls, is controlled by, or is under common control with that
Party. "Control," as used in this Section 1.1.1, means having the power to
direct, or cause the direction of, the management and policies of an entity,
whether through ownership of voting securities, by contract or otherwise.
Notwithstanding the foregoing, for purposes of this Agreement, the term
"Affiliate" does not include entities in which a Party or its Affiliates owns a
majority of the ordinary voting power to elect a majority of the board of
directors but is restricted from electing such majority by contract or
otherwise, until such time as such restrictions are no longer in effect.
1.1.2 "ANDA" means an Abbreviated New Drug Application, as
defined in the FD&C Act and applicable FDA rules and regulations.
-1-
1.1.3 "Batch" means a Manufacturing run of Product which
yields approximately one million two hundred thousand (1,200,000) tablets of
Product, as the same may be amended from time to time by the mutual written
agreement of the Parties.
1.1.4 "Certificate of Analysis" means the document identifying
the results of the Methods of Analysis for a specific Batch of Product in the
form agreed to by the Parties.
1.1.5 "CMC" has the meaning set forth in Section 3.1.1(ii).
1.1.6 "Commercially Reasonable Efforts" means efforts and
resources normally used by a Party for a compound or product owned by it or to
which it has rights, which is of similar market potential at a similar stage in
its product life, taking into account the competitiveness of the marketplace,
the proprietary position of the compound or product, the regulatory structure
involved, the profitability of the applicable products, and other relevant
factors. It is anticipated that the level of effort and resources may change at
different times during the product life cycle of a compound or product.
1.1.7 "Competing Product" has the meaning set forth in Section
2.3.
1.1.8 "Confidential Information" means either WCH Confidential
Information, IMPAX Confidential Information or both, as the context requires.
1.1.9 "Contract Year" means the period from the Effective Date
through May 31, 2003 and each consecutive twelve (12) month period thereafter
during the Term.
1.1.10 "Control" or "Controlled" in the context of
intellectual property rights means rights to intellectual property sufficient to
allow a grant of rights to a Party.
1.1.11 "Direct Development Cost" means (a) costs directly
attributable to an activity (i.e., those costs which vary with such activity),
including, but not limited to, direct labor and benefit expenses for such
activity and consumable bulk and other materials, as determined in accordance
with United States generally accepted cost accounting practices consistently
applied, plus (b) fixed overhead costs allocable to the activity, including, but
not limited to, direct benefit and labor expenses for technical services and
support services, depreciation, maintenance and repairs and insurance costs
associated with such activity, as determined in accordance with United States
generally accepted cost accounting practices consistently applied. In no event
shall any costs included in Direct Manufacturing Costs be included in Direct
Development Costs.
1.1.12 "Direct Manufacturing Cost" means (a) costs directly
attributable to Manufacturing, quality assurance and quality control related to
a unit of Product on a per tablet basis, including, but not limited to, direct
labor and benefit expenses for Manufacturing, and consumable bulk and other
product materials, as determined in accordance with United States generally
accepted cost accounting practices consistently applied, plus (b) fixed
Manufacturing overhead costs allocable to the Product based on the actual
percentage utilization (including start-up and shut-down time) of the capacity
of the manufacturing facility, including, but not limited to, direct benefit and
-2-
labor expenses for technical services and support services, depreciation,
maintenance and repairs and insurance costs associated with such utilization of
the manufacturing facility, as determined in accordance with United States
generally accepted cost accounting practices consistently applied. In no event
shall charges for (i) idle capacity or underutilized facilities or (ii) any
Direct Development Costs be included in Direct Manufacturing Costs.
1.1.13 "D-12 Product" means a twelve (12) hour extended
release tablet containing 5 mg Loratadine and 120 mg Pseudoephedrine meeting the
Specifications therefor.
1.1.14 "D-24 Product" means a twenty-four (24) hour extended
release tablet containing 10 mg Loratadine and 240 mg Pseudoephedrine meeting
the Specifications therefor.
1.1.15 "Effective Date" means the date determined pursuant to
Section 14.10.
1.1.16 "Exclusive Territory" means the world, except the
countries of China (including Hong Kong), Taiwan, Singapore, Malaysia, The
Philippines, Indonesia, Myanmar, Brunei, Cambodia, Vietnam, Thailand, Laos and
the Semi-Exclusive Territory.
1.1.17 "Facility" means IMPAX's facilities located at Hayward,
California or any other facility located in the United States approved in
writing by WCH for the Manufacture of Product, such approval not to be
unreasonably withheld or delayed.
1.1.18 "FDA" means the United States Food and Drug
Administration or any successor entity thereto.
1.1.19 "FD&C Act" means the Federal Food, Drug and Cosmetic
Act, as the same may be amended or supplemented from time to time.
1.1.20 "FTO Status" means that (i) final Regulatory Approval
(which includes without limitation WCH's consumer labeling and packaging) and,
if applicable, Pricing Approval to market Product have been obtained, (ii) all
legal claims, actions, proceedings and appeals with respect to a Product,
including without limitation the Patent Litigations, have been finally resolved
in WCH's and in IMPAX's favor or discontinued, and (iii) all relevant patents
have expired, been declared invalid or determined by WCH not to be infringed by
a Product.
1.1.21 "Good Clinical Practice" or "GCP" means the then
current standards for clinical trials for pharmaceuticals, as set forth in the
FD&C Act and applicable regulations promulgated thereunder, as amended from time
to time, and such standards of good clinical practice as are required by the
laws and regulations of the European Union and other Regulatory Authorities in
countries in which Products are intended to be sold, to the extent such
standards are not inconsistent with GCP under the FD&C Act.
1.1.22 "Good Laboratory Practice" or "GLP" means the then
current standards for laboratory activities for pharmaceuticals, as set forth in
the FD&C Act and applicable regulations promulgated thereunder, as amended from
time to time, and such standards of good laboratory practice as are required by
-3-
the laws and regulations of the European Union and other Regulatory Authorities
in countries in which Products are intended to be sold, to the extent such
standards are not inconsistent with GLP under the FD&C Act.
1.1.23 "Good Manufacturing Practice" or "GMP" means the then
current standards for the manufacture of pharmaceuticals, as set forth in the
FD&C Act and applicable regulations promulgated thereunder, as amended from time
to time, and such standards of good manufacturing practice as are required by
the applicable laws and regulations of the European Union and other Regulatory
Authorities in countries in which Products are intended to be sold, to the
extent such standards are not inconsistent with GMP under the FD&C Act.
1.1.24 "++" means the ++ for Loratadine and Product provided
in writing by WCH to IMPAX, as the same may be amended from time to time by the
mutual written agreement of the Parties.
1.1.25 "++" means the ++ provided in writing by WCH to IMPAX,
as the same may be amended from time to time by the mutual written agreement of
the Parties.
1.1.26 "IMPAX Confidential Information" means all Technical
Information pertaining to IMPAX's business or its Manufacturing operations
disclosed by IMPAX to WCH hereunder. It is understood and agreed that nothing in
this Agreement shall require IMPAX to disclose to WCH any of Schering
Corporation's confidential information or any other confidential information or
documentation that pertains solely to Schering Corporation and IMPAX hereby
agrees not to disclose any such information to WCH.
1.1.27 "IMPAX Patents" shall mean those Patents owned or
Controlled by IMPAX during the Term that claim a Product, its manufacture or
method of use, including the Patents which are set forth on Exhibit A hereto.
1.1.28 "Indemnified Party" has the meaning set forth in
Section 8.1.3.
1.1.29 "Indemnifying Party" has the meaning set forth in
Section 8.1.3.
1.1.30 "Launch" means the date on which Product in the OTC
Field is sold by WCH or one of its Affiliates for the first time to a Third
Party for commercial distribution in a particular country in the Territory.
1.1.31 "Loratadine" means pharmaceutical active ingredient
with the following chemical composition: ethyl 4-(8-chloro-5,
6-dihydro-11H-benzo [5,6] cyclohepta [1,2-b] pyridin-11-ylid-ene)-1
piperidinecarboxylate.
------------------
++ Confidential portions omitted and filed separately with the Commission.
-4-
1.1.32 "Manufacture," "Manufactured" or "Manufacturing" means
all activities involved in the production of Products to be supplied to WCH or
its Affiliates hereunder, including, without limitation, the preparation,
formulation, finishing, testing, packaging, storage and labeling of Products and
the handling, storage and disposal of any residues or wastes generated thereby.
1.1.33 "Materials" means all materials, including, without
limitation, all raw materials, ingredients, packaging supplies and labels,
required for the Manufacture of Products.
1.1.34 "Methods of Analysis" means the regulatory analytical
test methods for the D-12 Product set forth in ANDA 76-050 and for the D-24
Product set forth in ANDA 75-989, as the same may be amended from time to time
in accordance with the provisions of Section 5.3.
1.1.35 "NDA" means a New Drug Application, as defined in the
FD&C Act, and applicable FDA rules and regulations.
1.1.36 "Net Sales" means the gross invoice price for Product
sold by WCH or its Affiliates (or sublicensees pursuant to Section 2.1.2) to a
Third Party customer less the reasonable and customary accrual-basis deductions
from such gross amounts for: (i) normal and customary trade, cash and other
discounts, allowances and credits actually allowed and taken directly with
respect to sales of Product; (ii) credits or allowances actually granted for
damaged goods, returns or rejections of Product; (iii) sales or similar taxes
(including duties or other governmental charges levied on, absorbed or otherwise
imposed directly on the sales of Product, including, without limitation, value
added taxes or other governmental charges otherwise measured by the billing
amount) which are included in billing amount; (iv) uncollectible accounts; (v)
charge back payments and rebates granted to managed health care organizations or
to federal, state and local governments, their agencies and purchasers and
reimbursers or to trade customers, including but not limited to, wholesalers and
chain and pharmacy buying groups; and (vi) rebates (or equivalents thereof) that
are granted to or charged by national, state, provincial or local governmental
authorities. Such amounts shall be determined from the books and records of WCH,
its Affiliates and their respective sublicensees pursuant to Section 2.1.2
maintained in accordance with U.S. generally accepted accounting principles
consistently applied. Sales between or among WCH, its Affiliates and its
sublicensees pursuant to Section 2.1.2 shall be excluded from the computation of
Net Sales if such Affiliates or sublicensees are not end-users, but Net Sales
shall include the subsequent final sales to Third Parties by any such Affiliates
or sublicensees.
1.1.37 "OTC Field" means the area of non-prescription (i.e.,
not requiring, by law or regulation, a prescription from a medical doctor)
and/or over-the-counter sales for all human pharmaceutical uses.
1.1.38 "Party" means WCH or IMPAX or both, as the context
requires.
1.1.39 "Patent Litigations" has the meaning set forth in
Section 3.2.
-5-
1.1.40 "Patents" means all patents and patent applications,
and all additions, divisions, continuations, continuations in-part, pipeline
protection, substitutions, reissues, reexamination certificates, extensions,
registrations, patent term extensions, supplementary protection certificates and
renewals of any of the above.
1.1.41 "Person" means any natural person, corporation, general
partnership, limited partnership, proprietorship, other business organization,
trust, union, association or governmental authority.
1.1.42 "PPI Adjustment" has the meaning set forth in Section
6.3.2.
1.1.43 "Pricing Approval" means any approval for price or
reimbursement as may be necessary or appropriate as a prerequisite for marketing
any Product in the OTC Field in a particular country of the Territory.
1.1.44 "Product" means D-12 Product or D-24 Product or both,
as the context requires.
1.1.45 "Pseudoephedrine" means the pharmaceutical active
ingredient known as pseudoephedrine sulfate, USP.
1.1.46 "Recall" means any action by any Party to recover title
to or possession of Product sold or shipped to Third Parties or the failure by a
Party to sell or ship Product to Third Parties that would have been subject to
recall if it had been sold or shipped.
1.1.47 "Regulatory Approval" means all authorizations by the
competent Regulatory Authorities which are required for the manufacture,
marketing, promotion, pricing, sale and use of a Product in a given country or
regulatory jurisdiction in the Territory.
1.1.48 "Regulatory Authority" means any national,
supra-national, regional, state or local regulatory agency, department, bureau,
commission, council or other governmental entity involved in the granting of
Regulatory Approval and/or Pricing Approval for Products in a country in the
Territory.
1.1.49 "Regulatory Documents" means all regulatory
submissions, correspondence, and written descriptions and written accounts of
conversations, with Regulatory Authorities, Regulatory Approvals and Pricing
Approvals.
1.1.50 "Related Infringement" has the meaning set forth in
Section 11.2.1.
1.1.51 "Rolling Forecast" has the meaning set forth in Section
4.2.
1.1.52 "Seizure" means any action by FDA or any other
Regulatory Authority to detain or destroy Product or prevent the release of
Product.
-6-
1.1.53 "Semi-Exclusive Territory" means the countries of Japan
and Korea; "semi-exclusive license" means that IMPAX may either Manufacture and
sell Products for the OTC Field in its own name in each country in the
Semi-Exclusive Territory or license one (1) other Person (other that WCH) in
each country of the Semi-Exclusive Territory to make, have made, market,
promote, use, distribute, sell, have sold, import and export Products for the
OTC Field.
1.1.54 "Specifications" means the specifications for the D-12
Product set forth in ANDA 76-050 and for the D-24 Product set forth in ANDA
75-989, as the same may be amended from time to time in accordance with the
provisions of Section 5.3.
1.1.55 "Technical Information" means (a) techniques and data,
including ideas, inventions (including patentable inventions), practices,
methods, knowledge, know-how, trade secrets, skill, experience, documents,
apparatus, clinical and regulatory strategies, studies, test data, including
pharmacological, toxicological and clinical test data (including bioequivalence
studies), chemistry manufacturing and control data, analytical and quality
control data, manufacturing, patent data or descriptions relating to any
Product, and (b) chemical formulations, compositions of matter, product samples
and assays relating to any Product.
1.1.56 "Term" has the meaning set forth in Section 9.1.
1.1.57 "Territory" shall mean both the Exclusive and
Semi-Exclusive Territory.
1.1.58 "Third Party" means any Person other than WCH, IMPAX
and their respective Affiliates.
1.1.59 "WCH Confidential Information" means all Technical
Information and all information and data pertaining to WCH's business or
products disclosed by WCH to IMPAX hereunder, including, without limitation,
marketing and sales plans, artwork, formats, logos, drawings, customer lists and
operating procedures and all ordering and sales information.
1.1.60 "$" means United States dollars.
1.2 Construction of Certain Terms and Phrases. Unless the context of
this Agreement otherwise requires, (i) words of any gender include each other
gender; (ii) words using the singular or plural number also include the plural
or singular number, respectively; (ii) the terms "hereof," "herein," "hereby"
and derivative or similar words refer to this entire Agreement; (iv) the terms
"Article" or "Section" refer to the specified Article or Section of this
Agreement; and (v) Article and Section headings shall not affect the meaning or
construction of any provision of this Agreement.
-7-
ARTICLE II
GRANT OF RIGHTS; EXCLUSIVITY
2.1 Grant of License.
2.1.1 IMPAX hereby grants to WCH an exclusive license within
the Exclusive Territory and a semi-exclusive license within the Semi-Exclusive
Territory, both with the right to grant sublicenses, under the IMPAX Patents and
IMPAX's Technical Information and Regulatory Documents, to market, promote, use,
distribute, sell, have sold, import and export Products for the OTC Field during
the Term of this Agreement. WCH shall notify IMPAX in writing prior to having
the name of any Third Party on a Product label. Notwithstanding the exclusive
license set forth above, IMPAX shall be permitted to Manufacture and sell the
D-12 Product to Schering Corporation in the United States, its territories and
possessions.
2.1.2 IMPAX hereby grants WCH an exclusive license within the
Exclusive Territory and a semi-exclusive license within the Semi-Exclusive
Territory, both with the right to grant sublicenses, under the IMPAX Patents and
IMPAX's Technical Information and Regulatory Documents, to make and have made
Products for the OTC Field during the Term under the circumstances described in
Section 2.2. IMPAX shall provide WCH with a hard copy of IMPAX's Technical
Information, ANDA 76-050, ANDA 75-989 and Regulatory Documents relating to the
Products and WCH shall have the right to file such Technical Information, ANDAs
and Regulatory Documents with Regulatory Authorities, and reference the same in
WCH's applications for Regulatory Approval, as necessary or advisable to obtain
Regulatory Approval of Products. Upon WCH's request, IMPAX agrees to execute
such further documents requested by WCH evidencing WCH's rights hereunder. The
right to grant sublicenses of the rights granted under this Section 2.1.2 to
Affiliates and Third Parties shall be upon IMPAX's prior written consent, which
shall not be unreasonably withheld or delayed; provided however that any
sublicensee under this Section 2.1.2 must agree in writing to be bound by WCH's
obligations under this Agreement including but not limited to Article X and
Section 6.2. Notwithstanding the exclusive license set forth above, IMPAX shall
be permitted to grant Schering Corporation a license under the IMPAX Patents and
IMPAX's Technical Information and Regulatory Documents to make and have made the
D-12 Product in the United States, its territories and possessions.
2.2 Right to Manufacture. WCH shall have the right to manufacture
Products pursuant to the license set forth in Section 2.1.2 at any time after
(i) the fifth anniversary of the Launch of a Product in the United States by WCH
upon six (6) months' prior written notice to IMPAX or (ii) IMPAX notifies WCH
pursuant to the last sentence of Section 5.3.2 that a change required by the FDA
or other Regulatory Authority creates an unreasonable burden on IMPAX or results
in the continuing compliance by IMPAX with this Agreement uneconomical, so long
as WCH is not in breach of this Agreement as of the date such notice is
delivered. In such event, IMPAX shall furnish to WCH or its designee, on a
non-exclusive basis, all Technical Information relating to the Manufacture of
Products, including all manufacturing know-how, that is reasonably necessary to
enable WCH to make and have made Products and provide all technical assistance,
at WCH's cost, reasonably requested by WCH.
-8-
2.3 Exclusivity. During the Term, IMPAX and its Affiliates shall only
sell Product for the OTC Field in the Exclusive Territory to WCH and shall not
market, promote, use, distribute, sell, have sold, import, export, make or have
made either a twelve-hour or twenty-four hour, extended release Loratadine and
Pseudoephedrine combination product (other than the Products) which is, in
dosage strength, identical to either Product (a "Competing Product") to a Third
Party for the OTC Field in the Exclusive Territory. Notwithstanding the
foregoing, IMPAX shall be permitted (i) to Manufacture and sell D-12 Product to
Schering Corporation in the United States, its territories and possessions; and
(ii) to market, promote, use, distribute, sell, have sold, import, export, make
or have made a Competing Product that IMPAX or its Affiliate acquires through an
acquisition, divestiture, merger, joint venture or other business combination,
provided that such Competing Product did not account for more than seventy
percent (70%) of the sales of the business acquired by IMPAX or its Affiliate in
such transaction during the twelve (12) month period immediately preceding the
consummation of such transaction.
2.4 Non-Compete. During the Term, neither WCH nor its Affiliates shall
market, promote, use, distribute, sell, have sold, import, export, make or have
made a Competing Product for the OTC Field in the Territory. Notwithstanding the
foregoing, WCH and its Affiliates shall be permitted to market, promote, use,
distribute, sell, have sold, import, export, make or have made a Competing
Product acquired by WCH or its Affiliates through an acquisition, divestiture,
merger, joint venture or other business combination, provided that such
Competing Product did not account for more than seventy percent (70%) of the
sales of the business acquired by WCH or its Affiliate in such transaction
during the twelve (12) month period immediately preceding the consummation of
such transaction.
2.5 IMPAX Patents. IMPAX shall be responsible, at its cost and expense,
for prosecuting to issuance all patent applications within the IMPAX Patents,
for filing and prosecuting all patent reissues and re-examinations, for applying
for and obtaining any available patent term extensions and supplementary
protection certificates, and for paying all maintenance fees, on a large-entity
basis, on all patent applications and patents which constitute IMPAX Patents
under this Agreement.
2.6 Reservation of Rights. All rights under the IMPAX Patents, IMPAX's
Technical Information, IMPAX Confidential Information and IMPAX's Regulatory
Documents not expressly granted herein to WCH are reserved to IMPAX.
ARTICLE III
DEVELOPMENT ACTIVITIES AND PATENT LITIGATION
3.1 Development and Registration Responsibilities.
3.1.1 Prior to the Effective Date IMPAX has performed the
following development and registration activities:
-9-
(i) designed, conducted and met all bioequivalency test
requirements for Regulatory Approval by FDA in
accordance with FDA guidance documents;
(ii) designed and conducted all dosage form, formulation,
process, and chemistry manufacturing and control
("CMC") and related technical studies on Products,
including preparation of dosage form CMC regulatory
documents required for FDA review and approval of the
Products; and
(iii) FDA acceptance for filing of ANDA No. 76-050 and ANDA
No. 75-989 with FDA seeking approval of the D-12
Product and D-24 Product, respectively, as generic
prescription drugs and is prepared for FDA's
pre-approved inspection.
3.1.2 At WCH's request, IMPAX shall supplement and/or amend
ANDA No. 76-050 and ANDA No. 75-989 to include WCH's consumer labeling and
packaging and any other documentation necessary or advisable to support WCH's
consumer labeling and packaging for the OTC Field for the Products. IMPAX shall,
at its expense, (i) complete the construction, installation, commissioning, IQ,
OQ and PQ of all Facilities and all equipment necessary for Manufacture of
Products and (ii) conduct all scale up and validation activities for FDA
approval of Products.
3.1.3 IMPAX shall own and maintain ANDA No. 76-050 and ANDA
No. 75-989 and shall use its Commercially Reasonable Efforts to pursue, and at
its expense perform any additional development activities to obtain, final FDA
approval of these ANDAs for the OTC Field. WCH may submit applications for
Regulatory Approval for Products in the Territory as it deems advisable
(including NDAs); provided that WCH shall not be required to make any such
submissions for Regulatory Approval unless it determines to do so in its sole
discretion. Except for ANDA No. 76-050 and ANDA No. 75-989, WCH shall file, own
and maintain all other submissions for Regulatory Approval and Pricing Approval
of Products for the OTC Field in the Exclusive Territory. IMPAX shall be
responsible for providing the CMC and related technical components of such
submissions, as jointly determined by the Parties. Upon WCH's request and at
WCH's cost, IMPAX shall use Commercially Reasonable Efforts to provide
additional registration batches (including stability and analytical testing) and
required documentation to support any NDA that WCH may submit in the United
States. WCH shall bear the full cost of any additional studies required for
Regulatory Approval of the Products outside of the United States. To the extent
that IMPAX undertakes any additional development work which is not required for
FDA approval of a Product, at WCH's written request, to support Regulatory
Approval in the Territory outside the United States, WCH shall reimburse IMPAX
for the Direct Development Cost thereof.
3.1.4 The Parties shall cooperate with, and assist, each other
in connection with their activities hereunder including without limitation the
protocol for scale up and validation and addressing regulatory questions, and
preparing updates and supplements to regulatory filings for Product for the OTC
Field in the Territory. IMPAX shall be responsible for all communications with
-10-
FDA regarding ANDA No. 76-050 and ANDA No. 75-989. WCH shall be responsible for
all communications with the FDA and other Regulatory Authorities regarding
applications for Regulatory Approval submitted by WCH and post-Regulatory
Approval regulatory requirements for Product marketed by WCH for the OTC Field
in the Territory, including pharmacovigilance and Adverse Drug Experience
reporting, unless otherwise agreed in advance in writing by the Parties.
3.1.5 Each Party represents that it has complied and shall
comply with all applicable GLP, GCP and GMP in the conduct of the development
activity performed by it for the Products.
3.1.6 Upon WCH's request, IMPAX shall use Commercially
Reasonable Efforts to eliminate animal derived materials from the Products and
WCH shall reimburse IMPAX for the actual costs incurred by IMPAX (provided that
such are approved in writing by WCH prior to being incurred by IMPAX) in
connection therewith.
3.2 Patent Litigations. Schering Corporation ("Schering") has
instituted lawsuits against IMPAX for patent infringement with respect to the
D-12 Product and the D-24 Product. In Schering Corp. v. IMPAX Laboratories,
Inc., Civil Action No. 01-0520 (D.N.J.), Schering has charged infringement of
U.S. Patent 4,659,716 (the "'716 patent") with respect to the D-12 Product. In
Schering Corp. v. IMPAX Laboratories, Inc., Civil Action No. 01-0009 (D.N.J.),
Schering has charged infringement of both the '716 patent and U.S. Patent
5,314,697 (the "'697 patent") with respect to the D-24 Product (collectively,
Civil Action No. 01-0520 (D.N.J.) and Civil Action No. 01-0009 (D.N.J.), are
referred to herein as the "Patent Litigations"). Schering has also alleged in
both actions that it may be necessary in the future to expand the actions to
include claims for infringement of U.S. Patent 4,863,931 (the "'931 patent").
Both of these cases have been consolidated, for pretrial purposes, with other
patent infringement actions that Schering has filed against other defendants,
with this consolidated action identified as Schering Corp. v. Geneva
Pharmaceuticals, Inc., Civil Action Nos. 98-1259 (JAG)(GDH); 99-2237 (JAG)(GDH);
00-0255 (JAG)(GDH); 99-2820 (JAG)(GDH); 00-1439 (JAG)(GDH); 00-1657 (JAG)(GDH);
00-2944 (JAG)(GDH); 01-0009 (JAG)(GDH); 01-0279 (JAG)(GDH); 01-0520 (JAG)(GDH);
and 02-0328 (JAG)(GDH). IMPAX agrees to diligently defend the allegations
against it in the Patent Litigations and to use all reasonable efforts to have
the '716 and '697 patents (and also the '931 patent, to the extent any claims
are made in the future of infringement of the '931 patent) declared invalid,
unenforceable and/or not infringed by the D-12 Product and D-24 Product,
including, but not limited to, by defending all appeals by Schering, and by
filing and diligently prosecuting all reasonable appeals of any ruling or
decision adverse to IMPAX. WCH agrees to reasonably cooperate with IMPAX in the
conduct of the Patent Litigations and other proceedings involving WCH. All
liabilities, damages attorneys fees and other costs and expenses incurred in
connection with defending the Patent Litigations (including any claim of
infringement of the '931 patent) and defending and prosecuting all related
appeals shall be borne by IMPAX. IMPAX shall keep WCH promptly informed of any
material developments and shall from time to time consult with WCH regarding the
status of the Patent Litigations and shall provide WCH with copies of all
documents, not containing Schering's confidential information, which are filed
in, and all unprivileged written communications relating to the Patent
-11-
Litigations. Notwithstanding anything to the contrary in this Agreement but
subject to the next sentence, IMPAX shall have no obligation to supply either
Product to WCH prior to the earlier of (i) a United States District Court
decision that claims 1 and 3 of the '716 Patent are either invalid,
unenforceable or not infringed by such Product or (ii) October 21, 2004 and
IMPAX shall have no obligation to supply the D-24 Product to WCH prior to the
earlier of (i) a United States District Court decision that the '697 Patent is
either invalid, unenforceable or not infringed by the D-24 Product or (ii) April
23, 2013, unless after July 25, 2003 WCH provides IMPAX with an indemnity
agreement acceptable to IMPAX for any damages assessed against IMPAX for
infringement of such Patent prior to the occurrence of the first of such events,
such acceptance by IMPAX not to be unreasonably withheld or delayed. The
foregoing shall not relieve IMPAX of its obligation to supply WCH with Product
solely for uses reasonably related to the development and submission of
information under the FD&C Act.
3.3 Joint Defense Agreement. Promptly following the Effective Date, the
Parties shall enter into a joint defense agreement mutually acceptable to both
Parties containing customary terms and conditions for the purpose of, among
other things, preserving confidentiality and any applicable privilege attaching
to information and data exchanged by the Parties and pursuant to this Agreement.
IMPAX agrees to provide to WCH pursuant to the joint defense agreement a copy of
the written opinion of IMPAX's outside counsel, with copies of all documents
referenced in said opinion, regarding the validity or invalidity of ++ U.S.
Patent ++.
3.4 Product Launch. WCH shall not be required to Launch Products in any
country unless it determines, in its sole discretion, to do so. If WCH does not,
subject to supply by IMPAX of launch quantities of such Product pursuant to the
forecasts set forth in Section 4.2, use Commercially Reasonable Efforts to
Launch a Product in the OTC Field (i) in the United States within three (3)
months, or (ii) in the another country in the Territory within five (5) months,
following such Product having FTO Status for the OTC Field in such country, then
IMPAX, at its option and as its sole and exclusive remedy, may, upon written
notice to WCH, convert the licenses granted hereunder in such country for such
Product under the IMPAX Patents and Technical Information to non-exclusive
licenses (and thereby remove the restrictions placed on IMPAX in Section 2.3 for
such Product in such country) unless within thirty (30) days after such written
notice WCH Launches Product in the OTC Field in such country. Following the
Launch of a Product in any country of the Territory, WCH shall use Commercially
Reasonable Efforts to market such Product in such country; provided that nothing
shall require WCH to continue marketing a Product in a country if WCH
determines, in its sole judgment, that such Product may be subject to a
regulatory or other legal action or infringe any intellectual property right of
any Third Party in such country. WCH shall promptly notify IMPAX in writing of
such discontinuance. If within thirty (30) days after receipt of IMPAX's written
request, WCH does not resume marketing such Product in such country, then IMPAX,
at its option and as its sole and exclusive remedy, may, upon written notice to
WCH, convert the licenses granted hereunder in such country for such Product
under the IMPAX Patents and Technical Information to non-exclusive licenses (and
thereby remove the restrictions placed on IMPAX in Section 2.3 for such
-------------
++ Confidential portions omitted and filed separately with the Commission.
-12-
Product in such country). If at anytime after Launch of a Product in a country,
IMPAX reasonably believes that WCH is not using Commercially Reasonable Efforts
to market such Product in such country, then IMPAX shall notify WCH and if WCH
does not begin to use Commercially Reasonable Efforts to market such Product
within such country within thirty (30) days after such written notice, then
IMPAX, at its option and as its sole and exclusive remedy, may, upon written
notice to WCH, convert the licenses granted hereunder in such country for such
Product under the IMPAX Patents and Technical Information to non-exclusive
licenses (and thereby remove the restrictions placed on IMPAX in Section 2.3 for
such Product in such country).
ARTICLE IV
SUPPLY
4.1 Supply. During the Term, WCH shall order from IMPAX, subject to
WCH's right to Manufacture Products set forth in Section 2.2, WCH's requirements
of Products for the OTC Field in the Territory and IMPAX shall Manufacture and
deliver Products to WCH, subject to (i) WCH having complied with its obligation
to provide Rolling Forecasts pursuant to Section 4.2 and (ii) IMPAX's ability to
source active ingredient (provided that IMPAX has used Commercially Reasonable
Efforts to do so) in the event that such ability is impaired by WCH's refusal to
approve, or withdrawal of approval for, a supplier of active ingredient, in such
quantities, in such packaging and at such times as ordered by WCH. IMPAX shall
maintain the resources necessary to Manufacture Products at the Facility and
shall provide, at its own expense, all equipment, Materials and labor necessary
to do so. If IMPAX's Manufacturing obligations for all products that use the
same equipment and resources at the Facility as the Products exceed eighty five
percent (85%) of its total capacity for such equipment and resources at the
Facility for more than thirty (30) consecutive days, IMPAX shall notify WCH in
writing and, upon WCH's request, IMPAX shall use Commercially Reasonable Efforts
to increase its Manufacturing capacity at the Facility to maintain a better that
eighty five percent (85%) ratio. If any batch of Loratadine or Product fails to
meet the ++based on the ++ performed pursuant to Section 5.2, the Parties shall
be relieved of their respective obligations to supply and accept delivery of
Product relating to said failed batch.
4.2. Forecasts. At least four and one-half (4 1/2) months prior to the
anticipated Launch date (provided that the anticipated Launch date shall be at
least four and one-half (4 1/2) months after the date on which WCH provides
IMPAX with the ++ or notifies IMPAX in writing that none are required) in each
country of the Territory, WCH shall submit to IMPAX a forecast of the quantity
of Product that WCH anticipates ordering from IMPAX for such country during the
twelve (12) month period (broken down by Product and by month) following Launch
and every month thereafter at least three (3) months prior to the beginning of
the period covered by the forecast WCH shall update such forecast on a rolling
twelve (12) months basis (each, a "Rolling Forecast"). WCH shall place purchase
orders pursuant to Section 4.3 for at least the quantity of Product
---------------
++ Confidential portions omitted and filed separately with the Commission.
-13-
specified in the first three (3) months of each such Rolling Forecast and the
remaining nine (9) months shall be a non-binding estimate prepared by WCH using
Commercially Reasonable Efforts. Except as set forth in the immediately
preceding sentence, WCH shall not be required to order any fixed minimum
quantity of Product, notwithstanding any forecast or prior course of dealing. If
WCH fails to give IMPAX Rolling Forecasts as specified above after notice by
IMPAX of such failure the prior three (3) months Rolling Forecast shall apply.
IMPAX shall use Commercially Reasonable Efforts to allocate capacity at the
Facility to WCH so that it can supply WCH with ++ tablets of D-12 Product per
calendar month and ++ tablets of the D-24 Product per calendar month.
4.3 Orders and Delivery. WCH shall place its firm orders for Products
with IMPAX by submitting a purchase order which sets forth (i) the quantity of
Product ordered for delivery; and (ii) the delivery date for that order. Unless
IMPAX notifies WCH in writing within fifteen (15) days of receipt of a purchase
order that it is unable to deliver Products in accordance with such purchase
order, IMPAX shall be deemed to have accepted such purchase order as a binding
order. If IMPAX notifies WCH that it is unable to fill such purchase order, it
shall indicate the portion of such purchase order IMPAX cannot supply by the
requested delivery date and specify alternate delivery dates. WCH may cancel any
firm purchase order (in whole or in part) at any time prior to the delivery for
any quantity of Product; provided that, except in the event that this Agreement
is being terminated by WCH pursuant to Section 9.2, 9.3.3 or 9.3.4 or by IMPAX
pursuant to Section 5.3.2 or 9.2.3, (i) if IMPAX has completed the Manufacture
of Products pursuant to such firm purchase order, WCH shall pay the price
therefor and (ii) if IMPAX has commenced but not completed the Manufacture of
Product pursuant to such firm purchase order, WCH shall reimburse IMPAX for
Material and labor costs in respect of any works-in-progress or Materials orders
pursuant to such cancelled purchase order (or part thereof) at the time notice
of cancellation is received by IMPAX. All Products shall be delivered F.O.B. the
Facility in accordance with WCH's instructions. Time is of the essence for all
deliveries of Products.
4.4 Manufacturing Date. IMPAX shall schedule its Manufacturing
operations so that all Products delivered have the maximum shelf life reasonably
possible and in any event no Product delivered hereunder shall have less than
expiry less two (2) months of shelf life (unless a longer period of time is
agreed to by the Parties), based on the dating included on such Products'
packaging, remaining at the time of delivery.
4.5 Inconsistent Terms and Conditions. The terms and conditions of any
invoice, acknowledgement or similar document provided by IMPAX for Products, or
any terms and conditions of purchase orders provided by WCH for Products, which
are inconsistent with or in addition to the terms of this Agreement, shall be
null and void.
------------
++ Confidential portions omitted and filed separately with the Commission.
-14-
ARTICLE V
COMPLIANCE, QUALITY AND ENVIRONMENTAL
5.1 Compliance with Law. IMPAX and, if WCH is Manufacturing Product
pursuant to Section 2.2, WCH shall conduct its Manufacturing operations
hereunder in a safe and prudent manner, in compliance with all applicable laws
and regulations (including, but not limited to, those dealing with occupational
safety and health, those dealing with public safety and health, those dealing
with protecting the environment, and those dealing with disposal of wastes), and
in compliance with all applicable provisions of this Agreement. IMPAX and, if
WCH is Manufacturing Product pursuant to Section 2.2, WCH shall obtain all
necessary registrations and permits pertaining to activities contemplated by
this Agreement. To the extent necessary for the Regulatory Approval of Products,
IMPAX and, if WCH is Manufacturing Product pursuant to Section 2.2, WCH shall
permit the inspection of its premises by Regulatory Authorities and shall supply
all documentation and information to obtain or maintain Regulatory Approval of
Products.
5.2 Manufacturing Quality. IMPAX shall obtain all Materials from WCH
approved suppliers. All Products shall be Manufactured at the Facility and in
accordance with GMPs. IMPAX shall sample and analyze all Materials upon receipt
to ensure that such Materials are free of defects and meet the applicable
specifications therefor. Until WCH notifies IMPAX in writing that such practice
may be suspended or discontinued, IMPAX shall provide samples from each batch of
Loratadine to be used in the Manufacture of any Product and samples from each
Batch of Product to ++ (or such other contract laboratory specified by WCH) to
perform the ++ to ensure that such Loratadine and Product, as the case may be,
meet the ++. IMPAX shall promptly provide WCH with the results of such ++. ++
(or such other laboratory specified by WCH) shall xxxx WCH directly for such
services, and such amounts shall not be included in Direct Manufacturing Cost.
IMPAX shall not use any Loratadine in the Manufacture of Product that does not
meet the ++ and shall not ship any Product to WCH that does not meet the ++.
IMPAX shall take all necessary steps to prevent contamination and cross
contamination of Products. Products shall be unadulterated (within the meaning
of the FD&C Act) and free from contamination, diluents and foreign matter in any
amount. IMPAX shall perform the quality control tests with respect to Products
in accordance with the Methods of Analysis, the cost of the same to be included
in the price hereinafter specified. IMPAX shall promptly, upon completion of
such tests, deliver to WCH a copy of the record of such tests performed on, and
a Certificate of Analysis for, each Batch of Product. At WCH's request, IMPAX
shall deliver a representative sample (in the same amount as the sample that
IMPAX retains for its own purposes) from each Batch of Product to WCH's
designated representative. On the Effective Date or promptly thereafter, the
Parties shall execute and deliver to each other the Quality Agreement
substantially in the form of Exhibit C. Each Party agrees to perform its
respective obligations under the Quality Agreement in accordance with such
agreement.
----------------
++ Confidential portions omitted and filed separately with the Commission.
-15-
5.3 Manufacturing Changes.
5.3.1 IMPAX shall not make any changes to the Manufacturing
process, the Manufacturing equipment, the Specifications, the Materials, the
sources of Materials or the Methods of Analysis without the prior written
consent of WCH, which consent shall not be unreasonably withheld. If either
Party requests in writing a change in the Manufacturing process, the
Manufacturing equipment, the Specifications, the Materials, the source of
Materials or Methods of Analysis with respect to any Product that is not the
result of a requirement of FDA or any other Regulatory Authority, the other
Party shall use Commercially Reasonable Efforts to make or accept such change,
as the case may be. The requesting Party shall provide the other Party with a
detailed written report of all proposed changes to the Manufacturing process,
the Manufacturing equipment, the Specifications, the Materials, the sources of
Materials or the Methods of Analysis.
5.3.2 If FDA or any other Regulatory Authority requests or
requires any change in the Manufacturing process, the Manufacturing equipment,
the Specifications, the Materials, the source of Materials or Methods of
Analysis with respect to any Product the Parties shall meet and discuss an
implementation plan for such change and use all Commercially Reasonable Efforts
to accommodate such change to meet the FDA's or such other Regulatory
Authority's requirements. Each Party will bear its respective costs associated
with, or incurred as a result of, such change. Each Party agrees to promptly
forward to the other copies of any written communication received by such Party
from the FDA or any other Regulatory Authority that may affect the Manufacture
or supply of any Product as contemplated herein. Notwithstanding the foregoing,
if after Launch of the D-12 Product IMPAX determines, in the exercise of its
reasonable judgment, that a change required by the FDA or other Regulatory
Authority creates an unreasonable burden on IMPAX or results in the continuing
compliance by IMPAX with this Agreement uneconomical and if, upon IMPAX's
request, WCH does not agree (i) to pay the incremental cost of complying with
the changes required by FDA or such other Regulatory Authority (which costs
shall not be included in Direct Manufacturing Costs hereunder to the extent paid
by WCH), or (ii) to exercise its right to Manufacture pursuant to Section 2.2,
then IMPAX may by notice in writing to WCH, given no later than thirty (30) days
after such refusal by WCH, terminate this Agreement.
5.4 Testing by WCH. WCH may test the Product samples in accordance
with the applicable Methods of Analysis. If the analysis of any Product
performed by or for WCH differs from IMPAX's analysis of the same Batch, WCH
shall advise IMPAX and IMPAX and WCH agree to consult with each other in order
to explain and resolve the discrepancy between each other's determination. If,
after a good faith attempt by the Parties to do so, such consultation does not
resolve the discrepancy, an independent, reputable laboratory designated by WCH
and reasonably acceptable to IMPAX (such acceptance not to be unreasonably
withheld or delayed) shall repeat the applicable Methods of Analysis on
representative samples from such Batch provided by or for WCH. The costs of the
independent laboratory referred to above shall be borne by (i) WCH if such
laboratory determines that the Product conforms to the Specifications or (ii)
IMPAX if such laboratory determines that the Product does not conform to the
Specifications. If so requested by WCH in writing, IMPAX shall promptly send a
new Batch of Product (of similar quantity as to the amount of such Product being
-16-
analyzed as set forth above) to WCH. WCH shall not be obligated to pay for any
Product (and if WCH has paid for such Product IMPAX shall promptly reimburse
WCH) that such laboratory determines that does not conform to the
Specifications, but shall be obligated to pay for any new Batch of Product which
conforms to the Specifications that is sent as specified above, except that
IMPAX shall pay all transportation costs for such replacement Batch. If WCH
shall reject any Batch of Product, IMPAX's only obligation and liability to WCH
shall be to replace the rejected Batch of Product.
5.5 Samples and Record Retention. IMPAX shall retain records and
retention samples of each Batch of Product for at least thirty-six (36) months
after the expiration date of that Batch and shall make the same available to WCH
upon request. Retention samples shall only be destroyed after the required
holding period and then only after notice to WCH. During and after the Term,
IMPAX shall assist WCH with respect to any complaint, issue or investigation
relating to Product.
5.6 Inspection.
5.6.1 IMPAX shall give access to representatives of WCH, at
all reasonable times and upon reasonable notice during regular business hours,
to the Facility and any other facility in which Products are Manufactured,
tested and/or stored, and to all Manufacturing records with respect to Products
for the purpose of inspection. WCH shall have the right while at any such
Facility to inspect IMPAX's records, permits, and licenses to evaluate work
practices and compliance with all applicable FDA and other Regulatory Authority
laws and regulations, occupational health and safety, and environmental laws and
regulations, controlled substances laws and regulations, GMP and warehousing
practices and procedures. Upon WCH's request, IMPAX shall provide copies of
Batch records, quality control, quality assurance and validation documents
reasonably relating to the Product. Notwithstanding any inspection performed by
WCH, IMPAX shall remain solely responsible for operating its Facilities and for
complying with its obligations under this Agreement. Neither the rights granted
to WCH pursuant to this Section 5.6.1, nor any inspection performance by WCH,
shall impose any liability on WCH, except in the case of gross negligence or
willful misconduct on the part of WCH.
5.6.2 At any time during which WCH is Manufacturing Product
pursuant to Section 2.2, WCH shall give access to representatives of IMPAX, at
all reasonable times and upon reasonable notice during regular business hours,
to the facility in which Products are Manufactured, tested and/or stored, and to
all Manufacturing records with respect to Products, for the purpose of
inspection. IMPAX shall have the right while at any such facility to inspect
WCH's records, permits, and licenses to evaluate work practices and compliance
with all applicable FDA and other Regulatory Authority laws and regulations,
occupational health and safety, and environmental laws and regulations,
controlled substances laws and regulations, GMP and warehousing practices and
procedures. Upon IMPAX's request, WCH shall provide copies of Batch records,
quality control, quality assurance and validation documents reasonably related
to the Product. Notwithstanding any inspection performed by IMPAX, WCH shall
remain solely responsible for operating its facilities and for complying with
its obligations under this Agreement. Neither the rights granted to IMPAX
pursuant to this Section 5.6.2, nor any inspection performance by IMPAX, shall
impose any liability on IMPAX, except in the case of gross negligence or willful
misconduct on the part of IMPAX.
-17-
5.7 Adverse Drug Experience Reporting. Each Party shall fully,
accurately and promptly provide to the other Party with all data known to it at
any time during the term of this Agreement or thereafter, which data indicate
that any Product marketed by WCH is or may be unsafe, lacks utility, or
otherwise does not meet Specifications in accordance with the Adverse Event
Reporting Procedures set forth in Exhibit D attached hereto (as the same may be
amended from time to time by notice in writing from WCH to IMPAX). WCH shall
determine whether such information is required to be reported and report the
same as required, to FDA and any other Regulatory Authority.
5.8 Recalls and Seizure. Each Party shall keep the other Party
promptly and fully informed of any notification or other information whether
received directly or indirectly which might result in the Recall or Seizure of
Product. If either Party determines that it is necessary to Recall any Product,
it shall immediately notify the other Party. Prior to commencing any Recall, the
Parties shall review with one another the manner in which the Recall is to be
carried out and any instructions or suggestions of the applicable Regulatory
Authorities. IMPAX and WCH shall effect the Recall in the manner agreed upon
between the Parties in as expeditious a manner as possible and in such a way as
to cause the least disruption to the sales of any Products and to preserve the
goodwill and reputation associated with the Products and each Party. In any such
situation, WCH shall have the right to make all final decisions regarding such
Recall of the Products marketed by WCH.
5.9 Environmental, Occupational Health and Safety. IMPAX shall report
to WCH, and, if WCH is Manufacturing Product pursuant to Section 2.2, WCH shall
report to IMPAX, as soon as possible after any of the following incidents
related to the Manufacturing operations hereunder occurs:
(i) significant injuries or occupational illness;
(ii) property damage in excess of $50,000;
(iii) inspections by any environmental protection agency or
occupational health and safety agency; or
(iv) requests for information, notices of violations or
other significant governmental and safety agency
communications relating to environmental,
occupational health and safety compliance.
IMPAX shall only use waste haulers, brokers and disposal sites which
WCH has approved in writing for hazardous waste generated by the Manufacturing
operations, such approval not to be unreasonably withheld or delayed. IMPAX
shall have title to and be responsible for disposing in an environmentally safe
manner all residue and waste resulting from the Manufacturing operations
performed by it hereunder. IMPAX shall not use WCH trademarks or trade dress to
identify any waste materials or residues.
-18-
At any time during which WCH is Manufacturing Product pursuant to
Section 2.2, WCH shall only use waste haulers, brokers and disposal sites which
IMPAX has approved in writing for hazardous waste generated by the Manufacturing
operations, such approval not to be unreasonably withheld or delayed. WCH shall
have title to and be responsible for disposing in an environmentally safe manner
all residue and waste resulting from the Manufacturing operations performed by
it hereunder.
ARTICLE VI
LICENSE PAYMENTS, ROYALTIES, AND SUPPLY PRICE
6.1 License Payments. Subject to Section 9.3.3, WCH shall make the
following non-refundable license payments to IMPAX which shall be due and
payable one (1) time only and within thirty (30) days after the occurrence of
the corresponding event set forth below (provided that with respect to the
Product to which the event relates all prior events in the list involving such
Product have occurred; and provided further that this Agreement is in effect
with respect to the Product to which the event relates at the time of the
occurrence of such event and that notice of termination shall not have been
given pursuant to Section 9.3.2 with respect to the Product to which the event
relates prior to the occurrence of such event):
Event Payment
----- -------
(i) The Effective Date of this Agreement $++
(ii) Placement on stability of a D-12 Product pilot
batch in WCH's consumer blister packaging $++
(iii) Placement on stability of a D-24 Product pilot
batch in WCH's consumer blister packaging $++
-------------------
++ Confidential portions omitted and filed separately with the Commission.
-19-
Event Payment
----- -------
(iv) Filing with FDA an ANDA supplement/amendment
for D-12 Product to support 24 month expiry
based on stability studies in WCH's consumer
blister packaging $++
(v) Filing with FDA an ANDA supplement/amendment
for D-24 Product to support 24 month expiry
based on stability studies in WCH's consumer
blister packaging $++
(vi) WCH's acceptance of successful scale-up and
validation (based on WCH's approval of final
validation report) of D-12 Product $++
(vii) WCH's acceptance of successful scale-up and
validation (based on WCH's approval of final
validation report) of D-24 Product $++
(viii) The later to occur of (a) January 1, 2003 or
(b) final D-12 Product ANDA approval by FDA
with WCH's consumer labeling and blister
packaging $++
(ix) The later to occur of (a) January 1, 2003 or
(b) final D-24 Product ANDA approval by FDA
with WCH's consumer labeling and blister
packaging $++
(x) The later to occur of (a) January 1, 2003 or (b)
Launch of the D-12 Product by WCH in the United
States $++
(xi) The later to occur of (a) January 1, 2003 or (b)
Launch of the D-24 Product by WCH in the United
States $++
-----------------
++ Confidential portions omitted and filed separately with the Commission.
-20-
6.2 Royalties.
6.2.1 During the Term following the date of Launch of each
Product in a country of the Territory through the later of five (5) years from
Launch in such country and the expiration of the last to expire issued IMPAX
Patent in such country, if any, WCH shall pay to IMPAX, on a quarterly basis, a
royalty of ++ percent (++%) on Net Sales of such Product (whether or not
Manufactured by IMPAX, WCH pursuant to Section 2.2 or WCH's sublicensees
pursuant to Section 2.1.2) sold for the OTC Field on a country-by-country basis
in the Territory during the previous quarter.
6.2.2 During any period and for each country that royalties
are due and payable pursuant to Section 6.2.1, WCH shall, within thirty (30)
days after each calendar quarter for sales of Product for the OTC Field in the
United States and within sixty (60) days after each calendar quarter for sales
of Product for the OTC Field within the Territory outside the United States,
furnish to IMPAX a written quarterly report showing (i) the Net Sales of Product
for the OTC Field sold by WCH and its Affiliates and sublicensees pursuant to
Section 2.1.2 during the reporting period in such country; (ii) the royalties
which shall have accrued hereunder in respect of such sales in such country;
(iii) withholding taxes, if any, required by law to be deducted in respect of
such royalty payments; and (iv) the exchange rates used in determining the
amount of payment hereunder.
6.2.3 Payments accrued in each quarter shall be paid to IMPAX
no later than thirty (30) days after the end of such quarter for the United
States and no later than sixty (60) days after the end of such quarter for all
other countries. Any amounts not paid within thirty (30) days after the due date
thereof shall bear interest at the rate equal to eighteen percent (18%) per
annum.
6.2.4 All royalty payments to be made pursuant to this
Agreement shall be made in $. Amounts based on Net Sales in currencies other
than $ shall be converted to $ at the WCH financial statement exchange rate
applied by WCH on a consistent basis in WCH's own financial accounting on the
date such payment is due.
6.3 Supply Price.
6.3.1 IMPAX shall invoice WCH for the prices set forth in
Exhibit B attached hereto, subject to adjustment as set forth in Sections 6.3.2,
6.3.3 and 6.3.4, for all Products delivered to WCH hereunder. All prices are
inclusive of taxes, shipping costs to the point of delivery, customs duties and
other charges.
-----------------
++ Confidential portions omitted and filed separately with the Commission.
-21-
6.3.2 The Direct Manufacturing Cost, and the quality control,
Materials, labor and overhead components thereof, as of June 1, 2002 which
formed the basis of the price for each Product are set forth on Exhibit B
attached hereto. IMPAX shall use Commercially Reasonable Efforts to minimize the
Direct Manufacturing Cost of each Product. Commencing with June 1, 2003 and each
December 1st and June 1st thereafter (in each case, an "Adjustment Date"), IMPAX
may propose an adjustment to the prices to reflect documented changes in Direct
Manufacturing Cost per unit of Product on such June 1st or December 1st, as the
case may be, as compared to the Direct Manufacturing Cost per unit of Product on
June 1, 2002 for the first adjustment and thereafter on the immediately
preceding June 1st or December 1st, as the case may be, (without regard to
intervening fluctuations); provided that IMPAX gives WCH not less than ninety
(90) days' prior written notice of any proposed price increase and that IMPAX
may not increase the price of a Product more than once during any Contract Year;
and provided, further, that any such increase shall not exceed the relevant PPI
Adjustment. If WCH does not accept IMPAX's proposed price increases, the Parties
shall negotiate in good faith. If the Parties conclude their negotiations and
agree upon Product prices, such agreed upon price increases shall be effective
as of the expiration of such ninety (90) day notice period. In the event that
the Parties are unable to agree during the negotiations described above, this
Agreement shall be automatically terminated effective six (6) months after the
expiration of such ninety (90) day notice period. Until the date of such
termination, IMPAX shall supply WCH such Products at the prices then in effect
without such price increase. "PPI Adjustment" means the amount calculated in
accordance with the following formula:
DMC x PPI - BPPI
----------
BPPI
Where,
DMC = Direct Manufacturing Cost on June 1, 2002 for the first
adjustment and thereafter on the Adjustment Date immediately
preceding the Adjustment Date in question;
BPPI = the Bureau of Labor Statistics Producer's Price Index for
Pharmaceutical Preparations (Code 2834) on June 1, 2002 for
the first adjustment and thereafter on the Adjustment Date
immediately preceding the Adjustment Date in question; and
PPI = the Bureau of Labor Statistics Producer's Price Index for
Pharmaceutical Preparations (Code 2834) on the Adjustment
Date in question.
6.3.3 Continuous improvement initiatives, mutually agreeable
to the Parties shall be established to provide for continuous cost reductions
during the Term of this Agreement. Continuous improvement teams consisting of
equal representation from each Party shall use reasonable efforts to work to
identify and implement cost savings at a targeted rate of five percent (5%) of
WCH's purchase price per Contract Year, but the foregoing shall not constitute a
guarantee by IMPAX of any cost reductions. Any documented savings shall be
allocated to the Parties in proportion to the level of contribution by each
Party to realize the savings. Any cost savings allocated to WCH shall be in the
form of reduced purchase price.
-22-
6.3.4 Notwithstanding any provision herein to the contrary, if
at any time IMPAX makes sales of any Product to any person in any country of the
Territory at a price lower than the price then in effect hereunder for such
Product, such lower price shall be made available to WCH hereunder, with respect
to WCH's inventory of Product in such country as well as future purchases of
Product for resale in such country, for so long as IMPAX continues to make sales
to such person at such lower price.
6.3.5 WCH shall pay invoices for Products delivered hereunder
in $ not later than thirty (30) days after the later of receipt of Products
covered by such invoice and receipt of such invoice. In addition to its other
rights and remedies, IMPAX shall have the right to assess interest on amounts
past due by more than fifteen (15) days at the rate of one and one-half percent
(1 1/2%) per month, or the highest rate permissible by law, if lower.
6.4 Withholdings. Any and all income or similar taxes imposed or levied
on account of the receipt of payments under this Agreement which are required to
be withheld shall be paid by WCH on behalf of IMPAX and shall be paid to the
proper taxing authority. Proof of payment shall be secured, if available, and
sent to IMPAX by WCH as evidence of such payment in such form as required by the
tax authorities having jurisdiction over WCH. Such taxes shall be deducted from
the payments that would otherwise be remittable by WCH.
6.5 Audit Rights. WCH shall have the right, at its own expense, through
its independent certified public accountant (reasonably acceptable to IMPAX) to
access the books and records of IMPAX and its Affiliates, as may be reasonably
necessary, to verify the accuracy of IMPAX's Direct Development Costs and Direct
Manufacturing Costs. IMPAX shall have the right, at its own expense, through its
independent certified public accountant (reasonably acceptable to WCH) to access
the books and records of WCH and its Affiliates, as may be reasonably necessary,
to verify the accuracy of WCH's Net Sales. Such access shall be conducted after
thirty (30) days' prior written notice to the Party being audited and during
ordinary business hours and shall not be more frequent than once per Contract
Year or in respect of any Contract Year ending more than thirty-six (36) months
prior to the date of such notice. If such independent certified public
accountant's report shows any overpayment or underpayment by a Party, the other
Party shall remit to such Party within thirty (30) days after such Party's
receipt of such report, (i) the amount of such overpayment or underpayment, as
the case may be, (ii) interest on such overpayment or underpayment, as the case
may be, at the prime rate quoted by Chase Manhattan Bank N.A. from the date
payment was first due until the date of payment of such overpayment or
underpayment, as the case may be, and (iii) if such overpayment or underpayment,
as the case may be, exceeds five percent (5%) of the total amount owed for the
period then being audited, the reasonable fees and expenses of any independent
accountant performing the audit on behalf of such Party.
ARTICLE VII
REPRESENTATIONS AND WARRANTIES
7.1 Representation and Warranties of Each Party. Each of WCH and IMPAX
hereby represents and warrants to the other Party hereto as follows:
-23-
7.1.1 it is a corporation or entity duly organized and validly
existing under the laws of the state or other jurisdiction of incorporation or
formation;
7.1.2 the execution, delivery and performance of this
Agreement by such Party has been duly authorized by all requisite corporate
action and do not require any shareholder action or approval;
7.1.3 it has the power and authority to execute and deliver
this Agreement and to perform its obligations hereunder;
7.1.4 the execution, delivery and performance by such Party of
this Agreement and its compliance with the terms and provisions hereof does not
and will not conflict with or result in a breach of any of the terms and
provisions of or constitute a default under (i) any other contract entered into
by such Party; (ii) a loan agreement, guaranty, financing agreement, agreement
affecting a product or other agreement or instrument binding or affecting it or
its property; (iii) the provisions of its charter or operative documents or by
laws; or (iv) any order, writ, injunction or decree of any court or governmental
authority entered against it or by which any of its property is bound; and
7.1.5 is in compliance with all applicable laws and
regulations relating to its activities under this Agreement.
7.2 Representations and Warranties of IMPAX.
7.2.1 IMPAX hereby represents and warrants to WCH with respect
to each delivery of Products that:
(i) the Products (a) have been Manufactured in
the United States; (b) have been
Manufactured, stored and shipped in
accordance with GMPs and all applicable
laws, rules, regulations or requirements in
effect at the time of Manufacture; (c)
conform to the Specifications, are free from
defects and are merchantable; (d) at the
point of shipment to WCH or WCH's designee
are not adulterated or misbranded; and (e)
have been shipped and stored in accordance
with approved procedures agreed between WCH
and IMPAX;
(ii) the D-12 Products and D-24 Products are
pharmaceutically equivalent and
bioequivalent to CLARITIN-D(R) 12-hour
Extended Release Tablets and CLARITIN-D(R)
24-hour Extended Release Tablets,
respectively;
(iii) IMPAX has good and marketable title to all
Products and Products are free from all
liens, charges, encumbrances and security
interests;
-24-
(iv) to the knowledge of IMPAX, (A) as of the
Effective Date and (B) thereafter, except as
disclosed in writing by IMPAX to WCH, the
Manufacture, use, importation, offer for
sale and sale of Products do not infringe
any intellectual property rights of any
Third Party, including but not limited to
U.S. Patents 4,659,716; 4,863,931; ++; and
5,314,697 and any foreign counterparts
thereof;
(v) the Facilities conform in all respects to
applicable law governing such Facilities;
and
(vi) neither IMPAX nor its Affiliates used in any
capacity the services of any person debarred
under the U.S. Generic Drug Enforcement Act,
21 USA ss.335a(k)(l) and further it did not
use any person who has been convicted of a
crime as defined under the Generic Drug
Enforcement Act in connection with the
Manufacture of Products or any service
rendered to WCH.
7.2.2 IMPAX hereby represents and warrants with respect to the
IMPAX Patents and Technical Information:
(i) IMPAX has no knowledge that the IMPAX
Patents (a) are not valid and enforceable;
or (b) are dominated or the practice of then
claimed subject matter infringes the
intellectual property rights of any Third
Party in the Territory as of the Effective
Date;
(ii) IMPAX has the full right, power and
authority to grant the licenses set forth
in Sections 2.1 and 2.2;
(iii) IMPAX has not previously assigned,
transferred, conveyed or otherwise
encumbered its right, title and interest in
the Products, the IMPAX Patents or the
Technical Information in the OTC Field in
the Exclusive Territory; and
(iv) IMPAX is the sole and exclusive owner of the
IMPAX Patents and Technical Information free
and clear of all liens, charges,
encumbrances and security interests.
--------------
++ Confidential portions omitted and filed separately with the Commission.
-25-
7.3 Representations and Warranties of WCH.
7.3.1 WCH hereby represents and warrants to IMPAX that with
respect to any Product that WCH or one of its Affiliates Manufactures pursuant
to Section 2.2:
(i) such Products (a) have been Manufactured,
stored and shipped in accordance with GMPs
and all applicable laws, rules, regulations
or requirements in effect at the time of
Manufacture; (b) conform to the
Specifications, are free from defects and
are merchantable; (c) are not adulterated or
misbranded; and (d) have been shipped and
stored in accordance with approved
procedures agreed between WCH and IMPAX;
(ii) WCH's and/or its Affiliates' manufacturing
facilities for such Products conform in all
respects to applicable law governing such
facilities; and
(iii) neither WCH nor its Affiliates used in any
capacity the services of any person debarred
under the U.S. Generic Drug Enforcement Act,
21 USA ss.335a(k)(l) and further it did not
use any person who has been convicted of a
crime as defined under the Generic Drug
Enforcement Act in connection with the
Manufacture of Products.
7.3.2 WCH hereby represents and warrants to IMPAX that all
Products which WCH shall market, store, sell, distribute, import and export
under this Agreement shall have been marketed, stored, sold, distributed,
imported and exported in accordance with applicable law.
7.4 Representation by Legal Counsel. Each Party hereto represents that
it has been represented by legal counsel in connection with this Agreement and
acknowledges that it has participated in the drafting hereof. In interpreting
and applying the terms and provisions of this Agreement, the Parties agree that
no presumption shall exist or be implied against the Party which drafted such
terms and provisions.
7.5 No Further Warranties. EXCEPT AS OTHERWISE SPECIFICALLY PROVIDED IN
THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, CONCERNING THE PRODUCTS OR THE MERCHANTABILITY OR FITNESS THEREOF FOR
ANY PURPOSE.
ARTICLE VIII
INDEMNIFICATION AND INSURANCE
8.1 Indemnification.
8.1.1 IMPAX shall indemnify, defend and hold harmless WCH, its
Affiliates and their respective directors, officers, employees and agents from
and against all damages, losses, liabilities, expenses, claims, demands, suits,
-26-
penalties or judgments or administrative or judicial orders (including
reasonable attorneys' fees and expenses) ("Costs") incurred, assessed or
sustained by or against WCH, its directors, officers, employees or agents with
respect to or arising out of (i) the negligent or willful acts or omissions or
strict liability of IMPAX; (ii) any breach by IMPAX of its representations,
warranties or covenants hereunder; (iii) any Recall or Seizure attributable to
IMPAX's performance; (iv) any allegation that the Manufacture, importation,
sale, offer for sale or use of any Product in the United States infringes any
Patent or other proprietary or protected right, other than trademark rights; or
(v) IMPAX's failure to comply with any applicable law, regulation or order
(including but not limited to environmental laws, regulations and orders, and
laws and orders relating to the Manufacture, storage, sale, import and export of
Products).
8.1.2 WCH shall indemnify, defend and hold harmless IMPAX, its
Affiliates and their respective directors, officers, employees and agents from
and against all damages, losses, liabilities, expenses, claims, demands, suits,
penalties or judgments or administrative or judicial orders (including
reasonable attorneys' fees and expenses) incurred, assessed or sustained by or
against IMPAX, its directors, officers, employees or agents with respect to or
arising out of (i) the negligent or willful acts or omissions or strict
liability of WCH; or (ii) any breach by WCH of its representations, warranties
or covenants hereunder; or (iii) any Recall or Seizure attributable to WCH's
performance; (iv) any allegation that the importation, sale, offer for sale or
use of any Product by WCH in any country in the Exclusive Territory outside the
United States infringes any Patent or other proprietary or protected right; or
(v) WCH's failure to comply with any applicable law, regulation or order
(including but not limited to environmental laws, regulations and orders, and
laws and orders related to the Manufacture (if WCH is Manufacturing Product
pursuant to Section 2.2), storage, marketing, distribution, sale, import and
export of the Products).
8.1.3 Each Party and its Affiliates and their respective
directors, officers, employees or agents (an "Indemnified Party") shall promptly
notify the other Party (the "Indemnifying Party"), in writing, of any claim
asserted or threatened against such Indemnified Party for which such Indemnified
Party is entitled to indemnification hereunder from the Indemnifying Party. With
respect to any such claim the Indemnified Party shall, at no out-of-pocket
expense to it, reasonably cooperate with and provide such reasonable assistance
to such Indemnifying Party as such Indemnifying Party may reasonably request.
Such reasonable assistance may include, without limitation, providing copies of
all relevant correspondence and other materials that the Indemnifying Party may
reasonably request. The obligations of an Indemnifying Party under Sections
8.1.1 and 8.1.2 are conditioned upon the delivery of written notice to the
Indemnifying Party of any asserted or threatened claim promptly after the
Indemnified Party becomes aware of such claim; provided, that the failure of the
Indemnified Party to give such notice or any delay thereof shall not affect the
Indemnified Party's right to indemnification hereunder, except to the extent
that such failure or delay impairs the Indemnifying Party's ability to defend or
contest any such claim. The Indemnifying Party shall have the right to assume
the defense of any suit or claim for which indemnification is sought. If the
Indemnifying Party defends the suit or claim, the Indemnified Party may
participate in (but not control) the defense thereof at its sole cost and
expense. An Indemnifying Party may not settle a suit or claim, without the
consent of the Indemnified Party, if such settlement would impose any monetary
-27-
obligation on the Indemnified Party for which indemnification is not provided
hereunder or require the Indemnified Party to submit to an injunction or
otherwise limit the Indemnified Party's rights under this Agreement. Any payment
made by an Indemnifying Party to settle any such suit or claim shall be at its
own cost and expense.
8.1.4 With respect to any claim by one Party against the other
Party arising out of the performance or failure of performance of the other
Party under this Agreement, the Parties expressly agree that the liability of
such Party to the other Party for such breach shall be limited under this
Agreement or otherwise at law or equity to direct damages only and in no event
shall a Party be liable for lost profits, punitive, exemplary or consequential
damages; provided, however, that such limitation shall not apply with respect to
the obligations of either Party to indemnify the other under Sections 8.1.1 or
8.1.2 hereof in connection with a liability to a Third Party.
8.2 Insurance. Each Party shall maintain the following kinds of
insurance with the minimum limits set forth below.
Kind of Insurance Minimum Limits
----------------- --------------
Commercial General Liability, including $2,000,000 Per Occurrence
Contractual, Completed Operations and $5,000,000 Aggregate
Products Liability
Workers Compensation Statutory with Employer's Liability of
not less than $1,000,000 Per
Accident/Disease
Automobile Bodily Injury Liability $1,000,000 Each Accident
(including hired automobile and Combined Single Limit
non-ownership Liability)
WCH may be self insured for such amounts. Upon request, IMPAX shall
furnish insurance certificates as directed by WCH, satisfactory in form and
substance to WCH, showing the above coverages, and providing for at least ten
(10) days' prior written notice to WCH by the insurance company of cancellation
or modification. WCH shall be named as an additional insured on the IMPAX's
policies. Coverage shall be procured with carriers having an A.M. Best rating of
A-VII or better.
-28-
ARTICLE IX
TERM AND TERMINATION
9.1 Term. This Agreement shall commence on the Effective Date and
continue, unless sooner terminated as set forth below in this Article IX or in
Article XII or Sections 5.3.2, 6.3.2 or 14.10, until the later to occur of (i)
the fifth anniversary of the Launch date of a Product in the United States or
(ii) the date of the expiration of the last to expire of the IMPAX Patents (the
"Term").
9.2 Termination by Either Party.
9.2.1 If either Party shall materially breach any of its
obligations hereunder and shall fail to correct such breach within thirty (30)
days after the other Party shall have given notice to it thereof, the aggrieved
Party shall be entitled to notify the other Party that it intends to terminate
this Agreement unless such breach is corrected and may so terminate ten (10)
days after the end of such thirty (30) day period if such breach is continuing,
unless, to the extent the breach can be cured, the time period of thirty (30)
days is not sufficient to cure such breach in which event the Party in breach
shall have such additional time as shall be reasonably necessary to cure such
breach, but in no event to exceed six (6) months. Such termination shall not
give rise to the payment of any penalty, damages or indemnity by the terminating
Party.
9.2.2 If either Party by voluntary or involuntary action goes
into liquidation, dissolves or files a petition for bankruptcy or suspension of
payments, is adjudicated bankrupt, has a receiver or trustee appointed for its
property or estate, becomes insolvent or makes an assignment for the benefit of
creditors, the other Party shall be entitled by notice in writing to such Party
to terminate this Agreement forthwith. Such termination shall not give rise to
the payment of any penalty, damages or indemnity by the terminating Party.
9.2.3 If, upon the decision of a court of competent
jurisdiction from which either no appeal can be taken or the time for an appeal
has expired without an appeal having been filed, a claim is upheld that the
Manufacture, storage, importation, sale, offer to sell or use of the Product, or
Products, respectively, infringes any Patent or other proprietary or protected
right (other than trademark rights) of a Third Party, then either Party shall
have the right to immediately terminate this Agreement, upon written notice to
the other Party, as to the country or other geographic area, and Product, or
Products, respectively, covered by the Patent or other proprietary or protected
right. Upon any such termination by WCH, WCH shall have no further rights to
such Product or Products in that country or geographic area.
9.3 Termination by WCH.
9.3.1 WCH may terminate this Agreement upon ten (10) days'
written notice to IMPAX either in its entirety, or with respect to the Product
to which the event relates, if any of the following events does not occur by the
date set forth opposite such event:
-29-
Event Date
---- -----
(i) Successful completion of scale-up The later of (i) November 30, 2002 or
and validation (based on WCH's (ii) ninety (90) days from the date on
approval of final validation which WCH provides IMPAX with the ++
report) for the D-12 Product for the D-12 Product or notifies IMPAX
in writing that none are required
(ii) Successful completion of scale-up The later of (i) June 30, 2003
and validation (based on WCH's or (ii) ninety (90) days from
approval of final validation the date on which WCH provides
report) for the D-24 Product IMPAX with the ++ for the D-24 Product
or notifies IMPAX in writing that none
are required
(iii) Final ANDA approval (which includes August 30, 2003
without limitation WCH's consumer
labeling and blister packaging) of D-12
Product by FDA
(iv) Final ANDA approval (which includes March 31, 2004
without limitation WCH's consumer
labeling and blister packaging) of D-24
Product by FDA
(v) Failure to deliver at least Four and one-half (4 1/2) months after
seventy-five percent (75%) of the the later of (i) receipt of WCH's
Launch quantities of D-12 Product purchase order therefor or (ii) the
consistent with the forecasts date on which WCH provides IMPAX with
required by Section 4.2 the ++ for the D-12 Product or notifies
IMPAX in writing that none are required
---------------
++ Confidential portions omitted and filed separately with the Commission.
-30-
Event Date
----- ----
(vi) Failure to deliver at least Four and one-half (4 1/2) months after
seventy-five percent (75%) of the the later of (i) receipt of WCH's
Launch quantities of D-24 Product purchase order therefor or (ii) the
consistent with the forecasts date on which WCH provides IMPAX with
required by Section 4.2 the ++ for the D-24 Product or notifies
IMPAX in writing that none are required
Such termination shall not give rise to the payment of any penalty, damages or
indemnity by either Party and WCH shall have no further rights under Sections
2.1 and 2.2, except where the event is a failure to deliver Launch quantities of
the D-12 and D-24 Product in which case the provisions of Section 9.5.1 shall
apply.
9.3.2 WCH may terminate this Agreement either in its entirety
or with respect to any Product upon three (3) months' written notice to IMPAX.
If WCH terminates this Agreement pursuant to this Section 9.3.2, then WCH shall
make the following payments with respect to the Product so terminated:
Event Payment
----- -------
I. D-12 Product
If on or before the date on which notice of termination is given
for the D-12 Product the event described in Section 6.1(viii) has
not occurred $++
or
If on or before the date on which notice of termination is given
for the D-12 Product the event described in Section 6.1(viii) has
occurred but the event described in Section 6.1(x) has not
occurred $++
or
If on or before the date on which notice of termination is given
for the D-12 Product the event described in Section 6.1(x) has
occurred $++
---------------------
++ Confidential portions omitted and filed separately with the Commission.
-31-
II. D-24 Product
If on or before the date on which notice of termination is given
for the D-24 Product the event described in Section 6.1(ix) has
not occurred $++
or
If on or before the date on which notice of termination is given
for the D-24 Product the event described in Section 6.1(ix) has
occurred but the event described in Section 6.1(xi) has not
occurred $++
or
If on or before the date on which notice of termination is given
for the D-24 Product the event described in Section 6.1(xi) has
occurred $++
It is understood and agreed that the amounts set forth above are in lieu of and
not in addition to the license payments for the corresponding event set forth in
Section 6.1 and that, effective upon termination, WCH's obligation to make
future license payments with respect to any terminated Product shall be
canceled. Except as specifically set forth above, such termination shall not
give rise to the payment of any penalty, damages or indemnification by either
Party and WCH shall have no further rights to the Product or Products to which
such termination applies.
9.3.3 In addition to, and not in limitation on, WCH's rights
under Section 9.2.3, WCH may terminate this Agreement in its entirety or with
respect to any Product immediately (i) if FDA takes any action (provided that
with respect to such action either (a) no appeal can be taken or the time for an
appeal has expired without an appeal having been filed or an appeal has been
filed and FDA's action has been upheld or (b) such action is a final regulatory
action), the result of which is to prohibit the Manufacture, storage,
importation, sale, offer for sale or use of the Products or a Product,
respectively; (ii) if the Loratadine to be used by IMPAX to Manufacture Product
does not meet the ++ upon completion of the initial analysis by ++ (or such
other contract laboratory specified by WCH); provided that such notice of
termination is given by WCH in this subparagraph (ii) by no later than March 31,
2003; (iii) if the Loratadine to be used by IMPAX to Manufacture Product is not
determined upon testing by WCH to be outside the scope of ++ or any Patent that
issues based thereon; or (iv) if a decision is rendered in favor of Schering in
any of the Patent Litigations either by a United States District Court and the
time for an appeal has expired without an appeal having been filed, or by the
United States Court of Appeals for the Federal Circuit and the time for an
appeal has expired without an appeal having been filed, or by the United States
Supreme Court. Notwithstanding the foregoing, (a) if a United States District
Court renders a decision in favor of Schering with respect to the '716 Patent,
then WCH's obligation to make any further payments under Section 6.1 shall be
suspended until such time as the decision in favor of
-----------------
++ Confidential portions omitted and filed separately with the Commission.
-32-
Schering is reversed and a final decision from which no appeal can be taken is
entered in IMPAX's favor in such case; and (b) if a United States District Court
renders a decision in favor of Schering with respect to the '697 Patent, then
WCH's obligation to make any further payments under Section 6.1 with respect to
the D-24 Product shall be suspended until such time as the decision in favor of
Schering is reversed and a final decision from which no appeal can be taken is
entered in IMPAX's favor in such case. Such termination shall not give rise to
the payment of any penalty, damages or indemnity by WCH and WCH shall have no
further rights to such Product so terminated.
9.3.4 In addition to, and not in limitation on, WCH's rights
under Section 9.2.3, WCH may terminate this Agreement with respect to any
Product in a country (other than the United States which is provided for in
Section 9.3.3) in which a Regulatory Authority has taken any action (with
respect to such action either (a) no appeal can be taken, or the time for an
appeal has expired without an appeal having been filed or an appeal has been
filed and such Regulatory Authorities' action has been upheld or (b) such action
is a final regulatory action), the result of which is to prohibit the
Manufacture, storage, importation, sale, offer for sale or use of the Products
or a Product respectively, or an action is commenced alleging that the
Manufacture, storage, importation, sale, offer for sale or use of the Products
or a Product, respectively, infringe any Patent or other proprietary or
protected right of any Third Party in such country. Such termination shall not
give rise to the payment of any penalty, damages or indemnity by WCH and WCH
shall have no further rights to such country so terminated.
9.4 Termination by IMPAX.
9.4.1 If IMPAX requests in writing that WCH file an
application for Regulatory Approval for a Product in the OTC Field in a
particular country in the Exclusive or Semi-Exclusive Territory (other than the
United States) and if WCH does not commence using Commercially Reasonable
Efforts to submit such an application within six (6) months, then IMPAX, at its
option and as its sole and exclusive remedy, may terminate this Agreement with
respect to such Product in such country (thereby modifying the Exclusive or
Semi-Exclusive Territory to exclude such Product in such country) by providing
six (6) months' written notice to WCH, and WCH shall have no further rights to
such Product in such country. Such modification shall not give rise to the
payment of any penalty, damages or indemnification by either Party.
9.4.2 If WCH fails to use Commercially Reasonable Efforts to
Launch a Product in a country of the Exclusive or Semi-Exclusive Territory
within one (1) year after having obtained FTO Status for such Product in the OTC
Field in such country, IMPAX, at its option and as its sole and exclusive
remedy, may terminate this Agreement with respect to such Product in such
country (thereby modifying the Exclusive or Semi-Exclusive Territory to exclude
such Product in such country) by providing six (6) months' written notice to
WCH. Such modification shall not give rise to the payment of any penalty,
damages or indemnification by either Party and WCH shall have no further rights
to such Product in such country.
-33-
9.5 Effect of Expiration or Termination.
9.5.1 Upon expiration of this Agreement pursuant to Section
9.1 (i) or (ii) or termination by WCH pursuant to Section 9.2.2, 9.3.1(v) or
9.3.1(vi) or termination by IMPAX pursuant to 9.2.3 (provided that in the case
of termination by IMPAX pursuant to Section 9.2.3 only, (i) upon IMPAX's written
request prior to termination by IMPAX, WCH shall cooperate with IMPAX in
attempting to identify a means to address or avoid the subject infringement,
(ii) the license set forth below is limited to the countries or geographic area
to which such termination applies and (iii) WCH provides IMPAX with an indemnity
agreement acceptable to IMPAX for any damages assessed against IMPAX, arising
out of WCH's exercise of the license set forth below, for infringement of such
Patent or other proprietary or protected right, such acceptance not to be
unreasonably withheld or delayed), WCH shall have the fully paid-up, royalty
free, perpetual, irrevocable (except that such license may be terminated
pursuant to the proviso set forth below), non-exclusive license, with the right
to grant sublicenses, to make, have made, market, promote, use, distribute,
sell, have sold, import and export Products for the OTC Field within the
Territory pursuant to the Regulatory Documents, the IMPAX Patents and IMPAX's
Technical Information (including manufacturing know-how); provided that if WCH
breaches the terms of the license set forth in this Section 9.5.1 and fails to
correct such breach within ten (10) days after notice in writing from IMPAX,
IMPAX may terminate this license if such breach is continuing by notice in
writing given at the end of such ten (10) day period.
9.5.2 Upon termination of this Agreement by WCH for an uncured
material breach of this Agreement pursuant to Section 9.2.1, WCH shall have a
fully paid up, royalty free, perpetual, irrevocable (except that such license
may be terminated pursuant to the proviso set forth below), non-exclusive
license, with the right to grant sublicenses, to make, have made, market,
promote, use, distribute, sell, have sold, import and export Products for the
OTC Field within the Territory pursuant to the Regulatory Documents, the IMPAX
Patents and IMPAX's Technical Information (including manufacturing know-how);
provided that if WCH breaches the terms of the license set forth in this Section
9.5.2 and fails to correct such breach within ten (10) days after notice in
writing from IMPAX, IMPAX may terminate this license if such breach is
continuing by notice in writing given at the end of such ten (10) day period.
9.5.3 In the event that WCH terminates this Agreement under
the circumstances described in Section 9.5.1 or 9.5.2, (i) IMPAX shall promptly
but no later than within thirty (30) days after receipt of notice of such
termination, furnish to WCH, on a non-exclusive basis, all of IMPAX's Technical
Information (including manufacturing know-how) as relates to Product for the OTC
Field in the Territory and (ii) IMPAX shall, within thirty (30) days of a
request by WCH, furnish to WCH and/or its Affiliates all Regulatory Documents
which relate to Product for the OTC Field in the Territory. Upon WCH's request,
IMPAX shall within the same period deliver to WCH or its designees full copies,
at WCH's expense, (both paper and electronic, where available) of any Regulatory
Documents in IMPAX's or its Affiliates' possession or control and provide all
technical assistance, at WCH's cost, reasonably requested by WCH. IMPAX agrees
to promptly execute and deliver any additional documents and instruments, and
perform any additional acts, that may be reasonably necessary to effect this
right.
-34-
9.5.4 Except as otherwise set forth in this Agreement, neither
Party shall be entitled to any compensation whatsoever as a result of expiration
or termination of this Agreement, but without limiting either Party's damages
for any breach of this Agreement.
9.5.5 Termination or expiration of this Agreement, in whole or
in part, shall be without prejudice to the right of either Party to receive all
payments accrued and unpaid at the effective date of such termination or
expiration, without prejudice to the remedy of either Party in respect to any
previous breach of any of the representations, warranties or covenants herein
contained and without prejudice to any other provisions hereof which expressly
or necessarily call for performance after such termination or expiration.
9.5.6 The following provisions shall survive the expiration or
termination of this Agreement: Section 9.5 and Articles I, VII, VIII, X and XIV,
in each case for the time periods and subject to the limitations set forth
therein.
ARTICLE X
CONFIDENTIALITY
10.1 Nondisclosure Obligation. Each of IMPAX and WCH shall use only in
connection with the Manufacture of Product or otherwise in accordance with this
Agreement and shall not disclose to any Third Party the Confidential Information
received by it from the other Party pursuant to this Agreement, without the
prior written consent of the other Party. The foregoing obligations shall
survive for a period of five (5) years after the termination or expiration of
this Agreement. These obligations shall not apply to Confidential Information
that:
(i) is known by the receiving Party at the time of its
receipt, and not through a prior disclosure by the
disclosing Party, as documented by business records;
(ii) is at the time of disclosure or thereafter becomes
published or otherwise part of the public domain
without breach of this Agreement by the receiving
Party;
(iii) is subsequently disclosed to the receiving Party by a
Third Party who has the right to make such
disclosure;
(iv) is developed by the receiving Party independently of
the Confidential Information received from the
disclosing Party and such independent development can
be documented by the receiving Party; or
(v) is required by law, regulation, rule, act or order of
any governmental authority or agency to be disclosed
by a Party, provided that notice is promptly
delivered to the other Party in order to provide an
opportunity to seek a protective order or other
similar order with respect to such Confidential
Information and thereafter the disclosing Party
-35-
discloses to the requesting entity only the minimum
Confidential Information required to be disclosed in
order to comply with the request, whether or not a
protective order or other similar order is obtained
by the other Party.
10.2 Permitted Disclosures. Each Party may disclose the other Party's
Confidential Information to its employees and Affiliates on a need-to-know basis
and to its agents, counsel or consultants to the extent required to accomplish
the purposes of this Agreement; provided that the recipient Party obtains prior
agreement from such agents and consultants to whom disclosure is to be made to
hold in confidence and not make use of such Confidential Information for any
purpose other than those permitted by this Agreement. WCH may disclose IMPAX
Confidential Information in connection with seeking Regulatory Approval of
Products. Each Party will use at least the same standard of care as it uses to
protect proprietary or confidential information of its own to ensure that such
employees, agents, consultants, and Affiliates do not disclose or make any
unauthorized use of the other Party's Confidential Information, but in no event
less than a reasonable degree of care.
10.3 Disclosure of Agreement. Neither IMPAX nor WCH shall release to
any Third Party or publish in any way any non-public information with respect to
the terms of this Agreement without the prior written consent of the other
Party, which consent shall not be unreasonably withheld or delayed, provided
that, either Party may disclose the terms of this Agreement
(i) to the extent required to comply with applicable
laws, including, without limitation the rules and
regulations promulgated by the United States
Securities and Exchange Commission; provided,
further, that prior to making any such disclosure,
the Party intending to so disclose the terms of this
Agreement shall (a) provide the nondisclosing Party
with written notice of the proposed disclosure and an
opportunity to review and comment on the intended
disclosure which is reasonable under the
circumstances and (b) shall seek confidential
treatment for as much of the disclosure as is
reasonable under the circumstances, including,
without limitation, seeking confidential treatment of
any information as may be requested by the other
Party; or
(ii) to one or more Third Parties and/or their advisors in
connection with a proposed spin-off, joint venture,
divestiture, merger or other similar transaction
involving all, or substantially all, of the assets or
business of the disclosing Party to which this
Agreement relates or to lenders, investment bankers
and other financial institutions of its choice solely
for purposes of financing the business operations of
such Party; provided, further, that either (a) upon
the written consent of the other Party or (b) if the
disclosing Party uses reasonable efforts to obtain a
signed confidentiality agreement with such Third
Parties with respect to such information on terms no
less restrictive than those contained in this Article
X.
-36-
10.4 Publicity. Subject to Section 10.3, all publicity, press releases
and other announcements relating to this Agreement or the transactions
contemplated hereby shall be reviewed in advance by, and shall be subject to the
approval of, both Parties.
ARTICLE XI
TRADEMARKS; INFRINGEMENT OF IMPAX PATENTS
11.1 Trademarks. WCH may advertise, promote, market and sell Products
under any trademarks, copyrights, tradenames or logos, whether registered or
unregistered, selected by WCH in its sole discretion. IMPAX shall have no right,
title or interest in or to any such trademark, copyright, tradename or logo. So
long as WCH or any Affiliate of WCH shall have any interest in any such
trademark, copyright, tradename, or logo, whether registered or unregistered,
whether as proprietor, owner, or licensee in any country of the world, IMPAX
shall not adopt, use, apply for registration, register or own such trademark,
copyright, tradename, or logo, or any such item confusingly similar thereto in
any country of the world, or take any action which, in WCH's sole opinion,
weakens or undermines WCH's proprietary rights.
11.2 Infringement of IMPAX Patents.
11.2.1 Each Party shall promptly report in writing to the
other Party during the term of this Agreement any known infringement or
suspected infringement of any of the IMPAX Patents in the Territory by
manufacture, use or sale of a Product on a commercial scale in derogation of the
rights granted to WCH hereunder (hereinafter, a "Related Infringement") of which
it becomes aware, and shall provide the other Party with all available evidence
supporting said infringement or suspected infringement.
11.2.2 Except as provided in Section 11.2.4, IMPAX shall have
the right to initiate an infringement or other appropriate suit anywhere in the
Territory against any Third Party who at any time has infringed, or is suspected
of infringing, any of the IMPAX Patents. IMPAX shall give WCH sufficient advance
notice of its intent to file any suit on account of a Related Infringement and
the reasons therefor, and shall provide WCH with an opportunity to make
suggestions and comments regarding such suit. IMPAX shall keep WCH promptly
informed, and shall from time to time consult with WCH regarding the status of
any such suit on account of a Related Infringement and shall provide WCH with
copies of all documents filed in, and all written communications relating to,
such suit.
11.2.3 IMPAX shall have the sole and exclusive right to select
counsel for any suit referred to in Section 11.2.2 and shall, except as provided
below, pay all expenses of the suit, including without limitation attorneys'
fees and court costs. In the event that WCH elects not to contribute to the
costs of such litigation, IMPAX shall be entitled to retain any damages,
royalties, settlement fees or other consideration for infringement resulting
therefrom. If necessary, WCH shall join as a Party to the suit but shall be
under no obligation to participate except to the extent that such participation
is required as the result of being a named Party to the suit. WCH shall offer
reasonable assistance to IMPAX therewith at no charge to IMPAX except for
-37-
reimbursement of reasonable out-of-pocket expenses incurred in rendering such
assistance. WCH shall have the right to participate and be represented in any
such suit by its own counsel at its own expense. IMPAX shall not settle any such
suit on terms which grant any license to any other Party in derogation of the
rights granted to WCH hereunder without obtaining the prior written consent of
WCH, which consent shall not be unreasonably withheld.
11.2.4 In the event that IMPAX elects not to initiate an
infringement or other appropriate suit pursuant to Section 11.2.2 above on
account of a Related Infringement after reasonable efforts to xxxxx such Related
Infringement without litigation have failed, but in no event later than one
hundred and twenty (120) days after WCH's notice to IMPAX under Section 11.2.1,
IMPAX shall promptly advise WCH of its intent not to initiate such a suit, WCH
shall have the right, at the expense of WCH, of initiating an infringement or
other appropriate suit against the Party or Parties committing such Related
Infringement. In exercising its rights pursuant to this Section 11.2.4, WCH have
the sole and exclusive right to select counsel and shall, except as provided
below, pay all expenses of the suit including without limitation attorneys' fees
and court costs. IMPAX, in its sole discretion, may elect within sixty (60) days
after the commencement of such litigation, to contribute to the costs incurred
by WCH in connection with such litigation, and, if it so elects, any damages,
royalties, settlement fees or other consideration received by WCH as a result of
such litigation shall be shared by WCH and IMPAX pro rata based on their
respective sharing of the costs of such litigation provided that such pro rata
share shall not exceed fifty percent (50%) unless WCH has consented to a higher
share in writing. In the event that IMPAX elects not to contribute to the costs
of such litigation, WCH shall be entitled to retain any damages, royalties,
settlement fees or other consideration for infringement resulting therefrom. If
necessary, IMPAX shall join as a Party to the suit but shall be under no
obligation to participate except to the extent that such participation is
required as a result of being named a Party to the suit. At WCH's request, IMPAX
shall offer reasonable assistance to WCH in connection therewith at no charge to
WCH except for reimbursement of reasonable out-of-pocket expenses incurred in
rendering such assistance. IMPAX shall have the right to participate and be
represented in any such suit by its own counsel at its own expense.
ARTICLE XII
FORCE MAJEURE
12.1 Force Majeure. If the production, delivery, acceptance, or use of
Products specified for delivery under this Agreement, or the performance of any
other obligation of one of the Parties hereunder is prevented, restricted or
interfered with by reason of any cause or event beyond the reasonable control of
such Party and without the fault or negligence of such Party, the Party so
affected, upon prompt notice to the other Party (including a statement of
impact), shall be excused from performing such obligation during the continuance
of such event. If such event continues for a period of ninety (90) consecutive
days or more the other Party may terminate this Agreement by notice in writing
provided that such event of force majeure is continuing. If as a result or any
of the force majeure events described above, IMPAX is unable to fully supply
WCH's orders hereunder, IMPAX shall allocate all available quantities of
Materials and Products to WCH in the ratio that the quantities ordered by WCH in
twelve (12) month period immediately preceding such force majeure event bears to
IMPAX's requirements for it own use and for supply to Third Parties for that
same period; provided that if this Agreement has not been in effect for a full
twelve (12) month period, then such shorter period shall be used in lieu of a
twelve (12) month period.
-38-
ARTICLE XIII
NOTICES
13.1 Ordinary Notices. Correspondence, reports, documentation, and
any other communication in writing between the Parties in the course of ordinary
implementation of this Agreement shall be delivered by hand, sent by facsimile
or overnight courier to the employee or representative of the other Party who is
designated by such other Party to receive such written communication at the
address or facsimile numbers specified by such employee or representative.
13.2 Extraordinary Notices. Extraordinary notices and
communications (including without limitation, notices of termination, force
majeure, material breach, change of address, requests for disclosure of
Confidential Information, claims or indemnification) shall be in writing and
sent to each Party by prepaid registered or certified airmail, or by facsimile
confirmed by prepaid registered or certified airmail letter (and shall be deemed
to have been properly served to the addressee upon receipt of such written
communication) to the address set forth in Section 13.3 or such other address as
notified in writing by such Party to the other Party.
13.3 Addresses.
If to WCH:
Wyeth Consumer Healthcare
Five Giralda Farms
Madison, New Jersey 07940
Attention: President
Facsimile No.: 000-000-0000
With a copy to:
Wyeth
Five Giralda Farms
Madison, New Jersey 07940
Attention: General Counsel
Facsimile No.: 000-000-0000
If to IMPAX:
Impax Laboratories, Inc.
0000 Xxxxxx Xxxxxx
Xxxxxxxxxxxx, Xxxxxxxxxxxx 00000
Attention: Xxxxx X. Xxxxxxx, Co-Chief Executive Officer
Facsimile No.: 000-000-0000
-39-
With a copy to:
Xxx Xxxxxxx, Esq.
Blank, Rome, Comisky & XxXxxxxx LLP
Xxx Xxxxx Xxxxxx
Xxxxxxxxxxxx, Xxxxxxxxxxxx 00000-0000
Facsimile No.: 000-000-0000
ARTICLE XIV
MISCELLANEOUS
14.1 Governing Law. This Agreement shall be construed in accordance
with and governed by the law of the State of New York, without giving effect to
its conflict of laws provisions.
14.2 Equal Opportunity Clause. The Equal Opportunity Clause required by
Executive Orders 11246, as amended (41-CFR 60-1.4) and 11375, the Employment
Assistance to Veterans Clause required by Executive Order 11701 (41 CFR
60-250.4), the Vietnam Era Veteran Readjustment Act of 1972, the Employment of
the Handicapped Clause required by the Rehabilitation Act of 1973 (41 CFR
60-741.4) and the Americans with Disabilities Act of 1991 are part of this
Agreement and binding upon each Party unless exempted by rules, regulations or
orders of the Secretary of Labor. IMPAX agrees that the applicable clause with
regard to the utilization of minority contractors set forth at 41 CFR 1-1.303
and the applicable clause with regard to the Utilization of Small Business
Concerns and Small Business Concerns Owned and Controlled by Socially and
Economically Disadvantaged Individuals set forth at 41 CFR 1-1.13 are
incorporated herein by reference, as applicable. IMPAX agrees to provide
information and documentation with respect to the foregoing to WCH upon request.
14.3 Assignment. This Agreement shall not be assignable or transferable
by either Party hereto without the prior written consent of the other Party,
except that either Party may assign this Agreement without the other Party's
consent to the successor or the transferee of all, or substantially all, of the
Products, assets or business to which this Agreement relates or to one of its
Affiliates; provided that if IMPAX is the assigning Party, IMPAX also transfers
the Facility to such assignee. IMPAX shall not subcontract any of its work
hereunder without WCH's prior written consent and any such consent given by WCH
shall not release IMPAX from its obligations hereunder. WCH's sublicensing of
its obligations under this Agreement shall not release WCH from its obligations
hereunder. This Agreement shall be binding upon and shall inure to the benefit
of the Parties and their successors and permitted assigns.
14.4 Entire Agreement. This Agreement and all Exhibits attached hereto
(as the same may be amended from time to time by the written agreement of the
Parties) constitute the entire agreement between the Parties with respect to the
subject matter hereof and supersedes all other documents, agreements, verbal
consents, arrangements and understandings between the Parties with respect to
-40-
the subject matter hereof. This Agreement shall not be amended orally, but only
by an agreement in writing, signed by both Parties that states that it is an
amendment to this Agreement.
14.5 Severability. If any term of this Agreement shall be found to be
invalid, illegal or unenforceable, it is the intention of the parties that the
remainder of this Agreement shall not be affected thereby; provided that neither
Party's rights under this Agreement are materially adversely affected.
14.6 Independent Contractor. IMPAX shall act as an independent
contractor and neither Party shall have any authority to represent or bind the
other Party in any way.
14.7 No Waiver. Any waiver by one Party of any right or such Party or
obligation of the other Party must be in writing signed by the Party waiving
such right or performance of such obligation and shall not operate as a waiver
of any subsequent right or obligation.
14.8 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be an original and all of which together shall
constitute one and the same Agreement.
14.9 Compliance Issues. The Parties acknowledge that the export of
technical data, materials or products is subject to the exporting Party
receiving the necessary export licenses and that the Parties cannot be
responsible for any delays attributable to export controls which are beyond the
reasonable control of either Party and any such delay shall not constitute a
force majeure event or constitute a breach of this Agreement. The Parties agree
that regardless of any disclosure made by the Party receiving an export of any
ultimate destination of any technical data, materials or products, the receiving
Party will not re-export either directly or indirectly, any technical data,
material or products without first obtaining the applicable validated or general
license from the United States Department of Commerce, FDA and/or any other
agency or department of the United States Government as required.
14.10 HSR Filing. To the extent necessary, each of IMPAX and WCH
shall file as soon as practicable after the date this Agreement was signed by
each of the Parties, with the Federal Trade Commission (the "FTC") and the
Antitrust Division of the United States Department of Justice (the "Antitrust
Division") the notification and report form (the "Report") required under the
Xxxx-Xxxxx-Xxxxxx Antitrust Improvements Act of 1976, as amended, and the rules
and regulations promulgated thereunder ("HSR Act") with respect to the
transactions as contemplated hereby and shall reasonably cooperate with the
other Party to the extent necessary to assist the other Party in the preparation
of its Report and to proceed to obtain necessary approvals under the HSR Act,
including but not limited to the expiration or earlier termination of any and
all applicable waiting periods required by the HSR Act. Each Party shall bear
its own expenses, including, without limitation, legal fees, incurred in
connection with preparing such filings. If a Report is filed by the Parties
under the HSR Act, then the Effective Date shall be the date upon which the
necessary approvals have been obtained under the HSR Act or that the notice and
waiting period under the HSR Act has expired or been terminated.
-41-
If the Parties determine that no Report is required to be filed under
the HSR Act, the Effective Date shall be the date first written above.
In the event that a Report is required to be filed under the HSR Act,
either Party may, prior to the Effective Date, terminate this Agreement by
written notice to the other Party, if, within one hundred twenty (120) days
after this Agreement is signed by each of the Parties, approval of the
transactions contemplated by this Agreement under the HSR Act has not been
obtained or the notice and waiting period, as may be extended by the FTC, under
the HSR Act has not expired without adverse action regarding this Agreement or
the transactions contemplated hereby. If this Agreement is terminated pursuant
to this Section 14.10, then, notwithstanding any provision in this Agreement to
the contrary, neither Party shall have any further obligation to the other Party
with respect to the subject matter of this Agreement except for the obligations
set forth in Article X hereof, which obligations shall survive any termination
of this Agreement.
-42-
IN WITNESS WHEREOF, the Parties have executed this Agreement as of the
Effective Date.
WYETH,
acting through its Wyeth Consumer Healthcare Division
By: /s/ Xxxxxxx Xxxxxxx
-----------------------------------------------
Name: Xxxxxxx Xxxxxxx
Title: Vice President of Global Business
Development
IMPAX LABORATORIES, INC.
By: /s/ Xxxxx X. Xxxxxxx
-----------------------------------------------
Name: Xxxxx X. Xxxxxxx
Title: Co-Chief Executive Officer
-43-
